

Cancer Gene Therapy Market - 2024-2033

<https://marketpublishers.com/r/C2FE46834737EN.html>

Date: January 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: C2FE46834737EN

Abstracts

The Cancer Gene Therapy Market was valued at US\$ 3.97Billion in 2024 and is anticipated to reach US\$ 19.97Billion by 2033, at a CAGR of 0.198 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Gene Therapy Market.

This report delivers a comprehensive overview of the Cancer Gene Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Gene Therapy Market. The Cancer Gene Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Cancer Gene Therapy Market Scope:

Key Players

Novartis AG

Pfizer

Adaptimmune Therapeutics

Bluebird Bio, Inc.

Krystal Biotech, Inc.

Regulus Therapeutics

Biogen

Major Highlights

This report delivers a comprehensive overview of the Cancer Gene Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Gene Therapy Market. The Cancer Gene Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Therapy Type
- 2.4. Snippet by Indication
- 2.5. Snippet by End User
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Investment, Partnerships, and Product Approvals
 - 3.1.1.2. Rapid Technological Advances in Gene-Editing & Cell Engineering
 - 3.1.2. Restraints
 - 3.1.2.1. Regulatory Complexity and Safety/Immune Risks
 - 3.1.2.2. Very High Treatment and Manufacturing Costs
 - 3.1.3. Opportunity
 - 3.1.3.1. In-Vivo Delivery and Next-Gen Gene Therapy Platforms
 - 3.1.3.2. CDMO/Manufacturing Scale-Up and Emerging Market Expansion

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America

- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Patent Analysis
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics

5. CANCER GENE THERAPY MARKET, BY THERAPY TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
 - 5.1.2. Market Attractiveness Index, By Therapy Type
- 5.2. Gene Induced Immunotherapy*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Oncolytic Virotherapy
- 5.4. Gene Transfer Therapy

6. CANCER GENE THERAPY MARKET, BY INDICATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 6.1.2. Market Attractiveness Index, By Indication
- 6.2. Breast Cancer*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Brain Cancer
- 6.4. Lung Cancer
- 6.5. Pancreatic Cancer
- 6.6. Liver Cancer
- 6.7. Others

7. CANCER GENE THERAPY MARKET, BY END USER

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

- 7.1.2. Market Attractiveness Index, By End User
- 7.2. Hospitals*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Cancer Research Institutes
- 7.4. Biotechnology & Pharmaceutical Companies

8. CANCER GENE THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 8.1.2. Market Attractiveness Index, By Region
- 8.2. North America
 - 8.2.1. Introduction
 - 8.2.2. Key Region-Specific Dynamics
 - 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
 - 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 8.2.6.1. U.S.
 - 8.2.6.2. Canada
 - 8.2.6.3. Mexico
- 8.3. Europe
 - 8.3.1. Introduction
 - 8.3.2. Key Region-Specific Dynamics
 - 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
 - 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 8.3.6.1. Germany
 - 8.3.6.2. UK
 - 8.3.6.3. France
 - 8.3.6.4. Spain
 - 8.3.6.5. Italy
 - 8.3.6.6. Rest of Europe
- 8.4. Asia-Pacific
 - 8.4.1. Introduction
 - 8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. Brazil

8.5.6.2. Argentina

8.5.6.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players

9.2. Market Share Analysis and Positioning Matrix

9.3. Strategic Partnerships, Mergers & Acquisitions

9.4. Key Developments in Product Portfolios and Innovations

9.5. Company Benchmarking

10. COMPANY PROFILES

10.1. Novartis AG*

10.1.1. Company Overview

10.1.2. Product Portfolio

- 10.1.2.1. Product Description
- 10.1.2.2. Product Key Performance Indicators (KPIs)
- 10.1.3. Financial Overview
 - 10.1.3.1. Company Revenue
 - 10.1.3.2. Geographical Revenue Shares
 - 10.1.3.3. Revenue Forecasts
- 10.1.4. Key Developments
 - 10.1.4.1. Mergers & Acquisitions
 - 10.1.4.2. Key Product Development Activities
 - 10.1.4.3. Regulatory Approvals, etc.
- 10.1.5. SWOT Analysis
- 10.2. Pfizer
- 10.3. Adaptimmune Therapeutics
- 10.4. Bluebird Bio, Inc.
- 10.5. Krystal Biotech, Inc.
- 10.6. Regulus Therapeutics
- 10.7. Biogen (LIST NOT EXHAUSTIVE)

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: Cancer Gene Therapy Market - 2024-2033

Product link: <https://marketpublishers.com/r/C2FE46834737EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2FE46834737EN.html>